Voyager Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Voyager Therapeutics generated cash of $77,919,000, which is more than the previous year. Cash used in financing activities reached the amount of $33,645,000 last year. Net change in cash is therefore -$30,079,000.
Cash Flow
| 2014 | -11.91M | -3.30M | 22.12M |
|---|---|---|---|
| 2015 | 41.29M | -194.76M | 177.74M |
| 2016 | -42.48M | 47.3M | 514K |
| 2017 | -61.35M | -3.68M | 59.92M |
| 2018 | -15.88M | 26.46M | 4.74M |
| 2019 | 48.66M | -90.47M | 80.99M |
| 2020 | -96.71M | 112.99M | 3.16M |
| 2021 | -53.52M | 65.90M | 612K |
| 2022 | -12.50M | -7.33M | 1.11M |
| 2023 | 77.91M | -141.64M | 33.64M |
VYGR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 100.47M | 119.21M | 106.21M | 86.77M | 47.59M | 32.26M | 36.64M | 31.30M | 7.03M | 135K |
Operating activities | ||||||||||
Net income | 132.33M | -46.40M | -71.19M | 36.74M | -43.59M | -88.28M | -70.69M | -40.19M | -29.67M | -16.31M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4.44M | 6.19M | 5.16M | 3.81M | 2.76M | 2.11M | 1.59M | 612K | 600K | 184K |
Stock-based compensation expense | 11.15M | 9.34M | 11.32M | 14.93M | 15.64M | 0 | 9.23M | 6.31M | 4.02M | 425K |
| Deferred income tax benefit | 11.15M | 9.34M | 11.32M | 14.93M | 15.64M | 0 | 9.23M | 6.31M | 4.02M | 425K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -83.23M | 475K | 7.28M | 10.48M | -18.49M | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | -2.20M | -909K | 13.50M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -962K | 1.99M | -60K | -3.43M | 2.59M | -282K | 470K | -62K | -942K | 604K |
Cash generated by operating activities | 77.91M | -12.50M | -53.52M | -96.71M | 48.66M | -15.88M | -61.35M | -42.48M | 41.29M | -11.91M |
Investing activities | ||||||||||
Purchases Of Investments | -223.96M | -54.84M | -15.11M | -70.40M | -494.23M | -333.22M | -147.29M | -112.35M | -220.39M | 0 |
Investments In Property Plant And Equipment | -3.25M | -2.49M | -1.60M | -12.09M | -7.71M | -4.30M | -3.98M | -5.02M | -1.03M | -2.98M |
Acquisitions Net | 138.38M | 4.84M | -2.46M | -7.69M | 172K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -141.64M | -7.33M | 65.90M | 112.99M | -90.47M | 26.46M | -3.68M | 47.3M | -194.76M | -3.30M |
Financing activities | ||||||||||
Common Stock Issued | 31.12M | 1.11M | 612K | 3.16M | 77.61M | 0 | 57.99M | 0 | 104.77M | 80K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 481K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 33.64M | 1.11M | 612K | 3.16M | 80.99M | 4.74M | 59.92M | 514K | 177.74M | 22.12M |
Net Change In Cash | -30.07M | -18.73M | 12.99M | 19.44M | 39.18M | 15.32M | -5.11M | 5.33M | 24.27M | 6.9M |
Cash at end of period | 70.39M | 100.47M | 119.21M | 106.21M | 86.77M | 47.59M | 31.53M | 36.64M | 31.30M | 7.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |